Insider · CIK 1697422
Christopher R. Fenimore
EVP Finance CFO at Regeneron Pharmaceuticals REGN
Full history from EDGAR: holdings now, every transaction and Form 144 planned sales
Open-market buys0
Open-market sales84
Bought$0
Sold$30.3M
Every trade, with what the company filed around it
Open-market buys and sales as each Form 4 states them, newest first.
How these figures work
Notes on each row are as each Form 4 states them, next to SEC Tracker's own records of the company's filings and other insiders' buys. Holding after is what the filing reports they held after the trade, with the change in their holding.
| Date | Company | Trade | Value | Holding after | Notes |
|---|---|---|---|---|---|
| Aug 28, 2024 | Regeneron Pharmaceuticals REGN | Sold 228 sh at $1,204.79 The filing does not mark this sale as under a Rule 10b5-1 plan. 27 days after the company's 10-Q filed Aug 1, 2024. | $275K | 966 −19% | The filing does not mark this sale as under a Rule 10b5-1 plan. 27 days after the company's 10-Q filed Aug 1, 2024. |
| Aug 28, 2024 | Regeneron Pharmaceuticals REGN | Sold 766 sh at $1,205.44 The filing does not mark this sale as under a Rule 10b5-1 plan. 27 days after the company's 10-Q filed Aug 1, 2024. | $923K | 200 −79% | The filing does not mark this sale as under a Rule 10b5-1 plan. 27 days after the company's 10-Q filed Aug 1, 2024. |
| Aug 28, 2024 | Regeneron Pharmaceuticals REGN | Sold 200 sh at $1,206.30 The filing does not mark this sale as under a Rule 10b5-1 plan. 27 days after the company's 10-Q filed Aug 1, 2024. | $241K | 0 −100% | The filing does not mark this sale as under a Rule 10b5-1 plan. 27 days after the company's 10-Q filed Aug 1, 2024. |
| Aug 28, 2024 | Regeneron Pharmaceuticals REGN | Sold 2,237 sh at $1,204.71 The filing does not mark this sale as under a Rule 10b5-1 plan. 27 days after the company's 10-Q filed Aug 1, 2024. | $2.7M | 1,378 −62% | The filing does not mark this sale as under a Rule 10b5-1 plan. 27 days after the company's 10-Q filed Aug 1, 2024. |
| Aug 28, 2024 | Regeneron Pharmaceuticals REGN | Sold 928 sh at $1,205.49 The filing does not mark this sale as under a Rule 10b5-1 plan. 27 days after the company's 10-Q filed Aug 1, 2024. | $1.1M | 450 −67% | The filing does not mark this sale as under a Rule 10b5-1 plan. 27 days after the company's 10-Q filed Aug 1, 2024. |
| Aug 28, 2024 | Regeneron Pharmaceuticals REGN | Sold 450 sh at $1,206.15 The filing does not mark this sale as under a Rule 10b5-1 plan. 27 days after the company's 10-Q filed Aug 1, 2024. | $543K | 0 −100% | The filing does not mark this sale as under a Rule 10b5-1 plan. 27 days after the company's 10-Q filed Aug 1, 2024. |
| Aug 28, 2024 | Regeneron Pharmaceuticals REGN | Sold 236 sh at $1,205.67 The filing does not mark this sale as under a Rule 10b5-1 plan. 27 days after the company's 10-Q filed Aug 1, 2024. | $285K | 225 −51% | The filing does not mark this sale as under a Rule 10b5-1 plan. 27 days after the company's 10-Q filed Aug 1, 2024. |
| Aug 28, 2024 | Regeneron Pharmaceuticals REGN | Sold 200 sh at $1,206.70 The filing does not mark this sale as under a Rule 10b5-1 plan. 27 days after the company's 10-Q filed Aug 1, 2024. | $241K | 25 −89% | The filing does not mark this sale as under a Rule 10b5-1 plan. 27 days after the company's 10-Q filed Aug 1, 2024. |
| Aug 28, 2024 | Regeneron Pharmaceuticals REGN | Sold 235 sh at $1,205.67 The filing does not mark this sale as under a Rule 10b5-1 plan. 27 days after the company's 10-Q filed Aug 1, 2024. | $283K | 225 −51% | The filing does not mark this sale as under a Rule 10b5-1 plan. 27 days after the company's 10-Q filed Aug 1, 2024. |
| Aug 28, 2024 | Regeneron Pharmaceuticals REGN | Sold 200 sh at $1,206.67 The filing does not mark this sale as under a Rule 10b5-1 plan. 27 days after the company's 10-Q filed Aug 1, 2024. | $241K | 25 −89% | The filing does not mark this sale as under a Rule 10b5-1 plan. 27 days after the company's 10-Q filed Aug 1, 2024. |
| Feb 9, 2024 | Regeneron Pharmaceuticals REGN | Sold 344 sh at $950.49 The filing does not mark this sale as under a Rule 10b5-1 plan. 1 day after a Form 144 notice of a planned insider sale filed Feb 8, 2024. | $327K | 18,947 −2% | The filing does not mark this sale as under a Rule 10b5-1 plan. 1 day after a Form 144 notice of a planned insider sale filed Feb 8, 2024. |
| Feb 9, 2024 | Regeneron Pharmaceuticals REGN | Sold 487 sh at $951.39 The filing does not mark this sale as under a Rule 10b5-1 plan. 1 day after a Form 144 notice of a planned insider sale filed Feb 8, 2024. | $463K | 18,460 −3% | The filing does not mark this sale as under a Rule 10b5-1 plan. 1 day after a Form 144 notice of a planned insider sale filed Feb 8, 2024. |
| Feb 9, 2024 | Regeneron Pharmaceuticals REGN | Sold 1,046 sh at $952.62 The filing does not mark this sale as under a Rule 10b5-1 plan. 1 day after a Form 144 notice of a planned insider sale filed Feb 8, 2024. | $996K | 17,414 −6% | The filing does not mark this sale as under a Rule 10b5-1 plan. 1 day after a Form 144 notice of a planned insider sale filed Feb 8, 2024. |
| Feb 9, 2024 | Regeneron Pharmaceuticals REGN | Sold 1,342 sh at $953.47 The filing does not mark this sale as under a Rule 10b5-1 plan. 1 day after a Form 144 notice of a planned insider sale filed Feb 8, 2024. | $1.3M | 16,072 −8% | The filing does not mark this sale as under a Rule 10b5-1 plan. 1 day after a Form 144 notice of a planned insider sale filed Feb 8, 2024. |
| Feb 9, 2024 | Regeneron Pharmaceuticals REGN | Sold 1,100 sh at $954.57 The filing does not mark this sale as under a Rule 10b5-1 plan. 1 day after a Form 144 notice of a planned insider sale filed Feb 8, 2024. | $1.1M | 14,972 −7% | The filing does not mark this sale as under a Rule 10b5-1 plan. 1 day after a Form 144 notice of a planned insider sale filed Feb 8, 2024. |
| Feb 9, 2024 | Regeneron Pharmaceuticals REGN | Sold 600 sh at $955.00 The filing does not mark this sale as under a Rule 10b5-1 plan. 1 day after a Form 144 notice of a planned insider sale filed Feb 8, 2024. | $573K | 14,372 −4% | The filing does not mark this sale as under a Rule 10b5-1 plan. 1 day after a Form 144 notice of a planned insider sale filed Feb 8, 2024. |
| Dec 27, 2023 | Regeneron Pharmaceuticals REGN | Sold (10b5-1) 2,448 sh at $856.71 The filing says this sale was under a Rule 10b5-1 plan set up in advance. 55 days after the company's 8-K filed Nov 2, 2023. | $2.1M | 14,372 −15% | The filing says this sale was under a Rule 10b5-1 plan set up in advance. 55 days after the company's 8-K filed Nov 2, 2023. |
| Dec 22, 2023 | Regeneron Pharmaceuticals REGN | Sold (10b5-1) 250 sh at $846.27 The filing says this sale was under a Rule 10b5-1 plan set up in advance. 50 days after the company's 8-K filed Nov 2, 2023. | $212K | 16,820 −1% | The filing says this sale was under a Rule 10b5-1 plan set up in advance. 50 days after the company's 8-K filed Nov 2, 2023. |
| Dec 21, 2023 | Regeneron Pharmaceuticals REGN | Sold (10b5-1) 456 sh at $843.79 The filing says this sale was under a Rule 10b5-1 plan set up in advance. 49 days after the company's 8-K filed Nov 2, 2023. | $385K | 18,294 −2% | The filing says this sale was under a Rule 10b5-1 plan set up in advance. 49 days after the company's 8-K filed Nov 2, 2023. |
| Dec 21, 2023 | Regeneron Pharmaceuticals REGN | Sold (10b5-1) 1,224 sh at $844.09 The filing says this sale was under a Rule 10b5-1 plan set up in advance. 49 days after the company's 8-K filed Nov 2, 2023. | $1M | 17,070 −7% | The filing says this sale was under a Rule 10b5-1 plan set up in advance. 49 days after the company's 8-K filed Nov 2, 2023. |
| Mar 23, 2023 | Regeneron Pharmaceuticals REGN | Sold (10b5-1) 2,192 sh at $806.47 The filing says this sale was under a Rule 10b5-1 plan set up in advance. | $1.8M | 18,409 −11% | The filing says this sale was under a Rule 10b5-1 plan set up in advance. |
| Oct 5, 2022 | Regeneron Pharmaceuticals REGN | Sold (10b5-1) 1,844 sh at $749.00 The filing says this sale was under a Rule 10b5-1 plan set up in advance. | $1.4M | 16,425 −10% | The filing says this sale was under a Rule 10b5-1 plan set up in advance. |
| Oct 3, 2022 | Regeneron Pharmaceuticals REGN | Sold (10b5-1) 3,346 sh at $724.00 The filing says this sale was under a Rule 10b5-1 plan set up in advance. | $2.4M | 18,269 −15% | The filing says this sale was under a Rule 10b5-1 plan set up in advance. |
| Aug 23, 2021 | Regeneron Pharmaceuticals REGN | Sold (10b5-1) 4,576 sh at $655.00 The filing says this sale was under a Rule 10b5-1 plan set up in advance. | $3M | 27,944 −14% | The filing says this sale was under a Rule 10b5-1 plan set up in advance. |
| Aug 23, 2021 | Regeneron Pharmaceuticals REGN | Sold (10b5-1) 9 sh at $659.33 The filing says this sale was under a Rule 10b5-1 plan set up in advance. | $6K | 27,935 −<1% | The filing says this sale was under a Rule 10b5-1 plan set up in advance. |
| Aug 23, 2021 | Regeneron Pharmaceuticals REGN | Sold (10b5-1) 23 sh at $660.33 The filing says this sale was under a Rule 10b5-1 plan set up in advance. | $15K | 27,912 −<1% | The filing says this sale was under a Rule 10b5-1 plan set up in advance. |
| Aug 23, 2021 | Regeneron Pharmaceuticals REGN | Sold (10b5-1) 88 sh at $661.89 The filing says this sale was under a Rule 10b5-1 plan set up in advance. | $58K | 27,824 −<1% | The filing says this sale was under a Rule 10b5-1 plan set up in advance. |
| Aug 23, 2021 | Regeneron Pharmaceuticals REGN | Sold (10b5-1) 1 sh at $662.78 The filing says this sale was under a Rule 10b5-1 plan set up in advance. | $663 | 27,823 −<1% | The filing says this sale was under a Rule 10b5-1 plan set up in advance. |
| Aug 23, 2021 | Regeneron Pharmaceuticals REGN | Sold (10b5-1) 70 sh at $663.05 The filing says this sale was under a Rule 10b5-1 plan set up in advance. | $46K | 27,753 −<1% | The filing says this sale was under a Rule 10b5-1 plan set up in advance. |
| Aug 23, 2021 | Regeneron Pharmaceuticals REGN | Sold (10b5-1) 14 sh at $665.21 The filing says this sale was under a Rule 10b5-1 plan set up in advance. | $9K | 27,739 −<1% | The filing says this sale was under a Rule 10b5-1 plan set up in advance. |
| Jul 21, 2020 | Regeneron Pharmaceuticals REGN | Sold (10b5-1) 216 sh at $636.56 The filing says this sale was under a Rule 10b5-1 plan set up in advance. | $137K | 20,994 −1% | The filing says this sale was under a Rule 10b5-1 plan set up in advance. |
| Jul 21, 2020 | Regeneron Pharmaceuticals REGN | Sold (10b5-1) 154 sh at $637.88 The filing says this sale was under a Rule 10b5-1 plan set up in advance. | $98K | 20,840 −1% | The filing says this sale was under a Rule 10b5-1 plan set up in advance. |
| Jul 21, 2020 | Regeneron Pharmaceuticals REGN | Sold (10b5-1) 306 sh at $638.51 The filing says this sale was under a Rule 10b5-1 plan set up in advance. | $195K | 20,534 −1% | The filing says this sale was under a Rule 10b5-1 plan set up in advance. |
| Jul 21, 2020 | Regeneron Pharmaceuticals REGN | Sold (10b5-1) 75 sh at $639.64 The filing says this sale was under a Rule 10b5-1 plan set up in advance. | $48K | 20,459 −<1% | The filing says this sale was under a Rule 10b5-1 plan set up in advance. |
| Jul 21, 2020 | Regeneron Pharmaceuticals REGN | Sold (10b5-1) 113 sh at $640.61 The filing says this sale was under a Rule 10b5-1 plan set up in advance. | $72K | 20,346 −1% | The filing says this sale was under a Rule 10b5-1 plan set up in advance. |
| Jul 21, 2020 | Regeneron Pharmaceuticals REGN | Sold (10b5-1) 855 sh at $641.58 The filing says this sale was under a Rule 10b5-1 plan set up in advance. | $549K | 19,491 −4% | The filing says this sale was under a Rule 10b5-1 plan set up in advance. |
| Jul 21, 2020 | Regeneron Pharmaceuticals REGN | Sold (10b5-1) 676 sh at $642.39 The filing says this sale was under a Rule 10b5-1 plan set up in advance. | $434K | 18,815 −3% | The filing says this sale was under a Rule 10b5-1 plan set up in advance. |
| Jul 21, 2020 | Regeneron Pharmaceuticals REGN | Sold (10b5-1) 691 sh at $643.49 The filing says this sale was under a Rule 10b5-1 plan set up in advance. | $445K | 18,124 −4% | The filing says this sale was under a Rule 10b5-1 plan set up in advance. |
| Jul 21, 2020 | Regeneron Pharmaceuticals REGN | Sold (10b5-1) 303 sh at $644.57 The filing says this sale was under a Rule 10b5-1 plan set up in advance. | $195K | 17,821 −2% | The filing says this sale was under a Rule 10b5-1 plan set up in advance. |
| Jul 21, 2020 | Regeneron Pharmaceuticals REGN | Sold (10b5-1) 72 sh at $645.33 The filing says this sale was under a Rule 10b5-1 plan set up in advance. | $46K | 17,749 −<1% | The filing says this sale was under a Rule 10b5-1 plan set up in advance. |
| Jul 21, 2020 | Regeneron Pharmaceuticals REGN | Sold (10b5-1) 155 sh at $646.82 The filing says this sale was under a Rule 10b5-1 plan set up in advance. | $100K | 17,594 −1% | The filing says this sale was under a Rule 10b5-1 plan set up in advance. |
| Jul 21, 2020 | Regeneron Pharmaceuticals REGN | Sold (10b5-1) 82 sh at $647.79 The filing says this sale was under a Rule 10b5-1 plan set up in advance. | $53K | 17,512 −<1% | The filing says this sale was under a Rule 10b5-1 plan set up in advance. |
| Jul 21, 2020 | Regeneron Pharmaceuticals REGN | Sold (10b5-1) 11 sh at $658.00 The filing says this sale was under a Rule 10b5-1 plan set up in advance. | $7K | 17,501 −<1% | The filing says this sale was under a Rule 10b5-1 plan set up in advance. |
| Jun 16, 2020 | Regeneron Pharmaceuticals REGN | Sold (10b5-1) 112 sh at $581.40 The filing says this sale was under a Rule 10b5-1 plan set up in advance. | $65K | 18,721 −1% | The filing says this sale was under a Rule 10b5-1 plan set up in advance. |
| Jun 16, 2020 | Regeneron Pharmaceuticals REGN | Sold (10b5-1) 18 sh at $582.69 The filing says this sale was under a Rule 10b5-1 plan set up in advance. | $10K | 18,703 −<1% | The filing says this sale was under a Rule 10b5-1 plan set up in advance. |
| Jun 16, 2020 | Regeneron Pharmaceuticals REGN | Sold (10b5-1) 111 sh at $583.06 The filing says this sale was under a Rule 10b5-1 plan set up in advance. | $65K | 18,592 −1% | The filing says this sale was under a Rule 10b5-1 plan set up in advance. |
| Jun 16, 2020 | Regeneron Pharmaceuticals REGN | Sold (10b5-1) 99 sh at $584.62 The filing says this sale was under a Rule 10b5-1 plan set up in advance. | $58K | 18,493 −1% | The filing says this sale was under a Rule 10b5-1 plan set up in advance. |
| Jun 16, 2020 | Regeneron Pharmaceuticals REGN | Sold (10b5-1) 130 sh at $585.76 The filing says this sale was under a Rule 10b5-1 plan set up in advance. | $76K | 18,363 −1% | The filing says this sale was under a Rule 10b5-1 plan set up in advance. |
| Jun 16, 2020 | Regeneron Pharmaceuticals REGN | Sold (10b5-1) 413 sh at $586.54 The filing says this sale was under a Rule 10b5-1 plan set up in advance. | $242K | 17,950 −2% | The filing says this sale was under a Rule 10b5-1 plan set up in advance. |
| Jun 16, 2020 | Regeneron Pharmaceuticals REGN | Sold (10b5-1) 373 sh at $587.55 The filing says this sale was under a Rule 10b5-1 plan set up in advance. | $219K | 17,577 −2% | The filing says this sale was under a Rule 10b5-1 plan set up in advance. |
| Jun 16, 2020 | Regeneron Pharmaceuticals REGN | Sold (10b5-1) 147 sh at $588.80 The filing says this sale was under a Rule 10b5-1 plan set up in advance. | $87K | 17,430 −1% | The filing says this sale was under a Rule 10b5-1 plan set up in advance. |
| Jun 16, 2020 | Regeneron Pharmaceuticals REGN | Sold (10b5-1) 153 sh at $590.70 The filing says this sale was under a Rule 10b5-1 plan set up in advance. | $90K | 17,277 −1% | The filing says this sale was under a Rule 10b5-1 plan set up in advance. |
| Jun 16, 2020 | Regeneron Pharmaceuticals REGN | Sold (10b5-1) 233 sh at $591.61 The filing says this sale was under a Rule 10b5-1 plan set up in advance. | $138K | 17,044 −1% | The filing says this sale was under a Rule 10b5-1 plan set up in advance. |
| Jun 16, 2020 | Regeneron Pharmaceuticals REGN | Sold (10b5-1) 214 sh at $592.20 The filing says this sale was under a Rule 10b5-1 plan set up in advance. | $127K | 16,830 −1% | The filing says this sale was under a Rule 10b5-1 plan set up in advance. |
| Jun 16, 2020 | Regeneron Pharmaceuticals REGN | Sold (10b5-1) 109 sh at $593.25 The filing says this sale was under a Rule 10b5-1 plan set up in advance. | $65K | 16,721 −1% | The filing says this sale was under a Rule 10b5-1 plan set up in advance. |
| Jun 16, 2020 | Regeneron Pharmaceuticals REGN | Sold (10b5-1) 747 sh at $594.35 The filing says this sale was under a Rule 10b5-1 plan set up in advance. | $444K | 15,974 −4% | The filing says this sale was under a Rule 10b5-1 plan set up in advance. |
| Jun 16, 2020 | Regeneron Pharmaceuticals REGN | Sold (10b5-1) 403 sh at $595.50 The filing says this sale was under a Rule 10b5-1 plan set up in advance. | $240K | 15,571 −3% | The filing says this sale was under a Rule 10b5-1 plan set up in advance. |
| Jun 16, 2020 | Regeneron Pharmaceuticals REGN | Sold (10b5-1) 294 sh at $596.36 The filing says this sale was under a Rule 10b5-1 plan set up in advance. | $175K | 15,277 −2% | The filing says this sale was under a Rule 10b5-1 plan set up in advance. |
| Apr 1, 2020 | Regeneron Pharmaceuticals REGN | Sold (10b5-1) 63 sh at $478.77 The filing says this sale was under a Rule 10b5-1 plan set up in advance. | $30K | 14,234 −<1% | The filing says this sale was under a Rule 10b5-1 plan set up in advance. |
| Apr 1, 2020 | Regeneron Pharmaceuticals REGN | Sold (10b5-1) 69 sh at $479.00 The filing says this sale was under a Rule 10b5-1 plan set up in advance. | $33K | 14,165 −<1% | The filing says this sale was under a Rule 10b5-1 plan set up in advance. |
| Apr 1, 2020 | Regeneron Pharmaceuticals REGN | Sold (10b5-1) 58 sh at $480.28 The filing says this sale was under a Rule 10b5-1 plan set up in advance. | $28K | 14,107 −<1% | The filing says this sale was under a Rule 10b5-1 plan set up in advance. |
| Apr 1, 2020 | Regeneron Pharmaceuticals REGN | Sold (10b5-1) 62 sh at $482.09 The filing says this sale was under a Rule 10b5-1 plan set up in advance. | $30K | 14,045 −<1% | The filing says this sale was under a Rule 10b5-1 plan set up in advance. |
| Apr 1, 2020 | Regeneron Pharmaceuticals REGN | Sold (10b5-1) 124 sh at $483.58 The filing says this sale was under a Rule 10b5-1 plan set up in advance. | $60K | 13,921 −1% | The filing says this sale was under a Rule 10b5-1 plan set up in advance. |
| Apr 1, 2020 | Regeneron Pharmaceuticals REGN | Sold (10b5-1) 3 sh at $484.14 The filing says this sale was under a Rule 10b5-1 plan set up in advance. | $1K | 13,918 −<1% | The filing says this sale was under a Rule 10b5-1 plan set up in advance. |
| Apr 1, 2020 | Regeneron Pharmaceuticals REGN | Sold (10b5-1) 137 sh at $488.76 The filing says this sale was under a Rule 10b5-1 plan set up in advance. | $67K | 13,781 −1% | The filing says this sale was under a Rule 10b5-1 plan set up in advance. |
| Apr 1, 2020 | Regeneron Pharmaceuticals REGN | Sold (10b5-1) 201 sh at $489.48 The filing says this sale was under a Rule 10b5-1 plan set up in advance. | $98K | 13,580 −1% | The filing says this sale was under a Rule 10b5-1 plan set up in advance. |
| Apr 1, 2020 | Regeneron Pharmaceuticals REGN | Sold (10b5-1) 70 sh at $491.65 The filing says this sale was under a Rule 10b5-1 plan set up in advance. | $34K | 13,510 −1% | The filing says this sale was under a Rule 10b5-1 plan set up in advance. |
| Apr 1, 2020 | Regeneron Pharmaceuticals REGN | Sold (10b5-1) 134 sh at $492.45 The filing says this sale was under a Rule 10b5-1 plan set up in advance. | $66K | 13,376 −1% | The filing says this sale was under a Rule 10b5-1 plan set up in advance. |
| Apr 1, 2020 | Regeneron Pharmaceuticals REGN | Sold (10b5-1) 174 sh at $493.24 The filing says this sale was under a Rule 10b5-1 plan set up in advance. | $86K | 13,202 −1% | The filing says this sale was under a Rule 10b5-1 plan set up in advance. |
| Apr 1, 2020 | Regeneron Pharmaceuticals REGN | Sold (10b5-1) 37 sh at $494.16 The filing says this sale was under a Rule 10b5-1 plan set up in advance. | $18K | 13,165 −<1% | The filing says this sale was under a Rule 10b5-1 plan set up in advance. |
| Apr 1, 2020 | Regeneron Pharmaceuticals REGN | Sold (10b5-1) 68 sh at $497.99 The filing says this sale was under a Rule 10b5-1 plan set up in advance. | $34K | 13,097 −1% | The filing says this sale was under a Rule 10b5-1 plan set up in advance. |
| Dec 13, 2019 | Regeneron Pharmaceuticals REGN | Sold (10b5-1) 191 sh at $374.82 The filing says this sale was under a Rule 10b5-1 plan set up in advance. | $72K | 13,688 −1% | The filing says this sale was under a Rule 10b5-1 plan set up in advance. |
| Dec 13, 2019 | Regeneron Pharmaceuticals REGN | Sold (10b5-1) 624 sh at $375.58 The filing says this sale was under a Rule 10b5-1 plan set up in advance. | $234K | 13,064 −5% | The filing says this sale was under a Rule 10b5-1 plan set up in advance. |
| Dec 13, 2019 | Regeneron Pharmaceuticals REGN | Sold (10b5-1) 470 sh at $376.27 The filing says this sale was under a Rule 10b5-1 plan set up in advance. | $177K | 12,594 −4% | The filing says this sale was under a Rule 10b5-1 plan set up in advance. |
| Dec 13, 2019 | Regeneron Pharmaceuticals REGN | Sold (10b5-1) 346 sh at $377.38 The filing says this sale was under a Rule 10b5-1 plan set up in advance. | $131K | 12,248 −3% | The filing says this sale was under a Rule 10b5-1 plan set up in advance. |
| Dec 13, 2019 | Regeneron Pharmaceuticals REGN | Sold (10b5-1) 51 sh at $378.27 The filing says this sale was under a Rule 10b5-1 plan set up in advance. | $19K | 12,197 −<1% | The filing says this sale was under a Rule 10b5-1 plan set up in advance. |
| Dec 20, 2018 | Regeneron Pharmaceuticals REGN | Sold (10b5-1) 100 sh at $355.14 The filing says this sale was under a Rule 10b5-1 plan set up in advance. | $36K | 8,844 −1% | The filing says this sale was under a Rule 10b5-1 plan set up in advance. |
| Dec 20, 2018 | Regeneron Pharmaceuticals REGN | Sold (10b5-1) 348 sh at $356.27 The filing says this sale was under a Rule 10b5-1 plan set up in advance. | $124K | 8,496 −4% | The filing says this sale was under a Rule 10b5-1 plan set up in advance. |
| Dec 20, 2018 | Regeneron Pharmaceuticals REGN | Sold (10b5-1) 200 sh at $357.50 The filing says this sale was under a Rule 10b5-1 plan set up in advance. | $72K | 8,296 −2% | The filing says this sale was under a Rule 10b5-1 plan set up in advance. |
| Dec 20, 2018 | Regeneron Pharmaceuticals REGN | Sold (10b5-1) 200 sh at $358.27 The filing says this sale was under a Rule 10b5-1 plan set up in advance. | $72K | 8,096 −2% | The filing says this sale was under a Rule 10b5-1 plan set up in advance. |
| Dec 20, 2018 | Regeneron Pharmaceuticals REGN | Sold (10b5-1) 200 sh at $359.38 The filing says this sale was under a Rule 10b5-1 plan set up in advance. | $72K | 7,896 −2% | The filing says this sale was under a Rule 10b5-1 plan set up in advance. |
| Dec 20, 2018 | Regeneron Pharmaceuticals REGN | Sold (10b5-1) 500 sh at $360.40 The filing says this sale was under a Rule 10b5-1 plan set up in advance. | $180K | 7,396 −6% | The filing says this sale was under a Rule 10b5-1 plan set up in advance. |
| Dec 20, 2018 | Regeneron Pharmaceuticals REGN | Sold (10b5-1) 100 sh at $361.65 The filing says this sale was under a Rule 10b5-1 plan set up in advance. | $36K | 7,296 −1% | The filing says this sale was under a Rule 10b5-1 plan set up in advance. |
| Dec 20, 2018 | Regeneron Pharmaceuticals REGN | Sold (10b5-1) 200 sh at $362.45 The filing says this sale was under a Rule 10b5-1 plan set up in advance. | $72K | 7,096 −3% | The filing says this sale was under a Rule 10b5-1 plan set up in advance. |
Open-market trades are Form 4 transaction codes P (purchase) and S (sale). Planned sales are those the filing marks as made under a Rule 10b5-1 plan. A P-code buy at the offering price within a day of the company's FWP, 424B prospectus or offering 8-K is marked Bought in the offering and left out of open-market buy counts and cluster buys. Prices and values are as stated in each Form 4. Stock prices aren't shown on this page. Not investment advice.